Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy. - Wikidata - awgldk - TriplyDB

Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy.

Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy.

http://www.wikidata.org/entity/Q35626579

about

P62: An emerging oncotarget for osteolytic metastasis Autophagy-associated immune responses and cancer immunotherapy Pilot study of p62 DNA vaccine in dogs with mammary tumors Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent.p62/SQSTM1-Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer.P62 plasmid can alleviate diet-induced obesity and metabolic dysfunctions.Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors.Ginkgetin induces autophagic cell death through p62/SQSTM1-mediated autolysosome formation and redox setting in non-small cell lung cancer.Low neighbor of Brca1 gene expression predicts poor clinical outcome and resistance of sunitinib in clear cell renal cell carcinoma.p62/SQSTM1 interacts with vimentin to enhance breast cancer metastasis.

P2860

Q26753091-B8AAB5C5-33C5-4D20-8B47-DDC1C6410503 Q26770690-F7550449-10A8-4BCE-8E2E-4F8BAC7A77AD Q35149622-034904CA-DC8D-420D-B8A4-EBE7B5C5CB99 Q35551817-9299AA7F-B144-435E-9C39-EAA84946AFA6 Q38893853-36119ABD-CBA1-4719-B04C-69A66A6BC178 Q41348083-D949F35F-D26F-42DC-9265-05C0AFB289C7 Q41593373-3EFB19F4-0237-4431-A9DF-43A1A441899A Q46250932-7816BB0F-6A4E-41EF-B6D8-A70805B703E9 Q47161583-B5BF6D60-D028-44CE-9292-D24F89340D37 Q47715195-E8C10A61-BCFF-4FFD-9AFD-CFDDB3BA7A51

P2860

Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy.

http://www.wikidata.org/entity/Q35626579

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Feasibility analysis of p62 (S ...... a novel cancer immunotherapy.

@ast

Feasibility analysis of p62 (S ...... a novel cancer immunotherapy.

@en

type

label

Feasibility analysis of p62 (S ...... a novel cancer immunotherapy.

@ast

Feasibility analysis of p62 (S ...... a novel cancer immunotherapy.

@en

prefLabel

Feasibility analysis of p62 (S ...... a novel cancer immunotherapy.

@ast

Feasibility analysis of p62 (S ...... a novel cancer immunotherapy.

@en

P1433

Q35626579-7EA5F78D-92F9-4146-A7FF-A0A82F16D6D0

P1476

Q35626579-9AADAF20-A37F-4E25-8423-2334ED856F74

P2093

Q35626579-AEA7DDC1-01B0-4D99-A964-A5B14CC068DF

P2860

Q35626579-00343A4A-68A1-4D39-8E4F-1EF5171AB8B2

Q35626579-00DD7839-29EB-4932-87A1-846EEE93D009

Q35626579-0779BFC5-448C-4154-9A1A-59B6C8F8E2B2

Q35626579-09F87E63-AC80-429C-85A5-C027474427C7

Q35626579-12358982-D18A-45A8-8A27-FFAD98949131

Q35626579-14B228B1-0739-4E6E-9645-94FE66DA4746

Q35626579-1911ACF4-56F6-46AC-9BBB-1AD833548794

Q35626579-199F1840-A050-4AC3-AF8F-8136EBD705A4

Q35626579-1B954CF5-7EFC-4369-9568-00ED9589EE19

Q35626579-1C9FDA80-5B24-40BC-8B86-F6112350E44D

P304

Q35626579-74346CD9-75B0-424B-9F44-B41265326FFD

P31

Q35626579-F21BE284-7BD1-4258-8A62-DE51686797C1

Q35626579-edd1fbc0-2b21-4aa9-9377-426712520a30

P356

Q35626579-F397C34D-D5AB-4137-81E0-C770D39488FB

P433

Q35626579-E0F7AED3-9B2B-4FD2-97E8-8827A072C8CC

P478

Q35626579-AF1AB41E-4D91-4886-B874-FB0DFF47C96E

P50

Q35626579-57C988AD-7060-4C01-9C3F-56A3505A26B8

P577

Q35626579-E30E63A7-1A97-4897-94A3-5F377575291E

P5875

Q35626579-9A9D4E9D-42A5-4914-A2F7-14D69DC25772

P698

Q35626579-629602DD-C576-4221-98AA-04F2F5B9BD1B

P921

Q35626579-443F57FA-4C6A-4F2A-8FAE-595E1DADE9D9

Q35626579-7FFF30A2-7B26-4E7C-A9DA-D6F757EA2B43

Q35626579-CBF926D8-C55B-454E-B195-1F3BB30BFB28

Q35626579-F00BAC7F-C7AF-415A-A126-7D183018A846

P932

Q35626579-1BE8CECB-09C1-47D9-B3B1-D644E8322880

P356

08830185.2014.954699

P1433

International Reviews of Immunology

P1476

Feasibility analysis of p62 (SQSTM1)-encoding DNA vaccine as a novel cancer immunotherapy

@en

P2093

Victor I Shifrin

http://www.w3.org/2001/XMLSchema#string

P2860

p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription

A role for NBR1 in autophagosomal degradation of ubiquitinated substrates

Autophagy suppresses tumorigenesis through elimination of p62

Cancer immunoediting: from immunosurveillance to tumor escape

Development of a vaccine against pandemic influenza viruses: current status and perspectives.

Inhibition of influenza M2-induced cell death alleviates its negative contribution to vaccination efficiency.

Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma.

Regulation of cell proliferation and migration by p62 through stabilization of Twist1.

p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells.

Vaccines against cancer: Despite setbacks, attempts to harness the patient's immune system to fight tumor cells show promise in clinical trials

P304

375-382

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/08830185.2014.954699

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

33

http://www.w3.org/2001/XMLSchema#string

P50

Vladimir L. Gabai

P577

2014-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266402007

http://www.w3.org/2001/XMLSchema#string

P698

25277339

http://www.w3.org/2001/XMLSchema#string

P921

transport protein

P932

4438419

http://www.w3.org/2001/XMLSchema#string